16.05

3.20% -0.53

Quidelortho Corp (QDEL)

Overview News Price History Option Chain Financials Discussions Forecast

Quidelortho Corp stock is traded at $16.05, with a volume of 913.04K. It is down -3.20% in the last 24 hours and up +31.45% over the past month. QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

Previous Close:

$16.58

Open:

$16.77

24h Volume:

913.04K

Relative Volume:

0.49

Market Cap:

$1.09B

Revenue:

$2.66B

Net Income/Loss:

$-1.21B

P/E Ratio:

-0.9007

EPS:

-17.82

Net Cash Flow:

$-159.40M

1W Performance:

-7.65%

1M Performance:

+31.45%

6M Performance:

-42.86%

1Y Performance:

-39.04%

1-Day Range:

$16.00

$16.96

1-Week Range:

$15.54

$17.38

52-Week Range:

$9.92

$35.58

Quidelortho Corp Stock (QDEL) Company Profile

Name

Quidelortho Corp

Sector

Healthcare (1071)

Industry

Medical Devices (140)

Phone

(858) 552-1100

Address

9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA

Employee

6,500

Twitter

@QuidelDX

Next Earnings Date

2026-08-04

Latest SEC Filings

QDEL's Discussions on Twitter

Compare QDEL vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
QDEL Quidelortho Corp	16.05	1.09B	2.66B	-1.21B	-159.40M	-17.82
ABT Abbott Laboratories	103.06	179.51B	46.59B	5.41B	7.38B	3.0938
SYK Stryker Corp	330.25	126.60B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	83.21	106.51B	36.36B	4.84B	5.43B	3.7261
BSX Boston Scientific Corp	44.25	65.77B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	82.63	47.58B	6.30B	1.07B	1.09B	1.8406

Quidelortho Corp Stock (QDEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-25	Downgrade	Citigroup	Buy → Neutral
May-08-25	Upgrade	Jefferies	Hold → Buy
Dec-11-24	Upgrade	Citigroup	Neutral → Buy
Dec-10-24	Initiated	Jefferies	Hold
Sep-19-24	Resumed	UBS	Neutral
Sep-05-24	Upgrade	Craig Hallum	Hold → Buy
Mar-04-24	Downgrade	UBS	Neutral → Sell
Feb-14-24	Downgrade	JP Morgan	Neutral → Underweight
Dec-11-23	Downgrade	Citigroup	Buy → Neutral
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Oct-14-22	Upgrade	UBS	Sell → Neutral
Sep-19-22	Initiated	Citigroup	Neutral
Jul-20-22	Initiated	UBS	Sell
Jun-17-22	Resumed	JP Morgan	Neutral
Feb-22-22	Upgrade	Raymond James	Outperform → Strong Buy
Jan-22-21	Upgrade	Raymond James	Mkt Perform → Outperform
May-12-20	Downgrade	JP Morgan	Neutral → Underweight
Mar-26-20	Downgrade	Barclays	Overweight → Equal Weight
Oct-23-18	Resumed	Raymond James	Strong Buy
Mar-08-18	Upgrade	Raymond James	Outperform → Strong Buy
Jan-22-18	Reiterated	Barclays	Overweight
Jan-04-18	Upgrade	CL King	Neutral → Buy
Sep-19-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-17	Upgrade	Canaccord Genuity	Hold → Buy
Jul-18-17	Upgrade	William Blair	Mkt Perform → Outperform
Apr-25-17	Reiterated	Canaccord Genuity	Hold
Feb-17-17	Initiated	CL King	Neutral
Dec-16-16	Downgrade	Piper Jaffray	Overweight → Neutral
Jun-13-16	Upgrade	Raymond James	Mkt Perform → Outperform
Feb-18-16	Reiterated	Barclays	Overweight
Feb-09-16	Downgrade	Canaccord Genuity	Buy → Hold
Jan-08-16	Reiterated	Canaccord Genuity	Buy
Dec-14-15	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-02-15	Initiated	Barclays	Overweight
Jul-31-13	Reiterated	Canaccord Genuity	Buy
Mar-03-11	Downgrade	Wedbush	Outperform → Neutral

View All

Quidelortho Corp Stock (QDEL) Latest News

Jul 24, 2026

Beyond Fentanyl: How the Drug Crisis Is Changing – Company Announcement - Financial Times

Jul 23, 2026

Jul 21, 2026